Navigation Links
Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Date:12/11/2007

i-tumor activity to CHOP-R with fewer severe side effects. In the interim analysis, 78 patients were evaluated for safety and 40 patients were evaluated for efficacy. A reduction in the incidence of severe heart damage (LVEF decline >15 percent, 2/36 patients for CPOP-R vs. 7/36 patients for CHOP-R) was seen. Declines in LVEF greater than or equal to 10% have occurred equally in both arms (8 patients each). In addition, reductions in grade 3 infections (2 patients for CPOP-R vs. 7 patients for CHOP-R) and febrile neutropenia (2 patients for CPOP-R vs. 7 patients for CHOP-R) were reported in this early interim analysis.

Based on investigator assessments after four cycles of therapy, 40 patients were evaluated for efficacy, of which 33 percent achieved a complete response (CR) and 53 percent achieved a partial response (PR) on the CPOP-R arm (n=21) compared to 32 percent achieving a CR and 52 percent achieving a PR on the doxorubicin arm (n=19).

There were three deaths within 30 days of the last dose of study treatment on the CPOP-R arm. Two of the events were attributed to study treatment (pneumonia concurrent with neutropenia and non-cardiogenic pulmonary edema concurrent with non-neutropenic infection). No deaths within 30 days of the last dose of the study drug were reported in the CHOP-R arm.

Details of the RAPID Trial

The RAPID (Replacing Adriamycin with Pixantrone to Improve Safety in NHL Disease) trial is a randomized controlled phase II/III combination study in up to 280 patients investigating whether the substitution of pixantrone for doxorubicin in the first-line treatment of patients with advanced aggressive NHL can provide a comparable major response rate while reducing known clinically important doxorubicin-related toxicities. This multi-center international trial randomizes newly diagnosed patients to either the standard of care regimen CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) or an inves
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy versus Placebo for IBS Symptoms
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
8. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
9. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
10. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
11. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...B-0040 at Children,s Hospital, Health Sciences Cen...swire/ -- Enobia Pharma, an emerging Canadian biot...cs for serious bone disorders, today announced tha... for hypophosphatasia was dosed. Enobia is investi...040 for the treatment of this rare and often cripp...
(Date:12/1/2008)...FirstCall/ -- Following a,Request for Proposal is...ed,third generation smallpox vaccine, Public Wor...he Canadian Department of National Defence, has aw...ery of IMVAMUNE(R). , The Canadian authorit...try,s bio-preparedness programme. , The con...
(Date:11/30/2008)...ire/ -- Older adults who exercise regularly show i...of small blood vessels in the brain, according to ...the Radiological Society of North America (RSNA). ...y of North Carolina ( UNC) - Chapel Hill , is the...exercise to brain scans of those who do not. , ...
(Date:11/27/2008)...stic leukemia relapse cases arise from a cell alre...MPHIS, Tenn., Nov. 27 S... have identified distinctive genetic changes in th...c leukemia (ALL) that cause relapse. The finding o...lapse in children and, ultimately, in adults. , ...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Healthways Enters German Healthcare Market 3004 1Healthways Enters German Healthcare Market 3004 2Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday October 25 2007 1095 1Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday October 25 2007 1095 2Grid computing offers new hope in race against bird flu 3001 1Grid computing offers new hope in race against bird flu 3001 2Fair play in chimpanzees 698 1Fair play in chimpanzees 698 2
...ril 04, 2007 /PRNewswire/ -- Novagali Pharma, an,e...zed in,ophthalmology, announces today positive res...R) in children suffering from Vernal,Keratoconjunc...n,that both symptoms and signs of disease improved...e tolerability to Vekacia(R),was excellent. , VKC ...
...INESS WIRE)--Apr 4, 2007 - CytRx Corporation,(NASD...ional animal,stroke studies indicating that CytRx,...celerated the recovery of sensory and,motor functi...en,treatment was withheld as long as 48 hours afte...d upon preclinical data,announced by CytRx in Dece...
Other Medicine Technology:Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 2CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 3CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 4CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 5
(Date:12/1/2008)...alker Chooses Two Tampa Beneficiaries for Par and ...AMPA, Fla., Dec. 1 The ...rity of Tampa Bay, Inc. and the Judeo Christian He...he 2009 Par and Poker Celebrity Challenge for Char..., , "It is only appropriate that events like...
(Date:12/1/2008)...the sunlight-derived nutrient tied to increased ca...HealthDay News) -- A lack of vitamin D, which is ...elps boost the risk of heart attacks and strokes, ...of studies linking increased cardiovascular risk w...efe, director of preventive cardiology at the Mid ...
(Date:12/1/2008)..., Dec. 1, 2008 The Arthritis Foundation announces...or research in arthritis. The recipients, Dr. Gera...Physicians and Dr. Michel Nussenzweig of Rockefell...ed research advancements in the cure and control o...zed for his research in the development and functi...
(Date:12/1/2008)... Va., Dec. 1 The Food A...d Julia E. Bradsher, Ph.D., as its new CEO, replac..., , Dr. Bradsher brings to FAAN extensive kn...l allergic reaction. For the past six years, as Se...team and strategic planning for all Dey Pharmaceut...
Breaking Medicine News(10 mins):Health News:Celebrity Event Gives Local Non-Profits a Reason to be Thankful 2Health News:Vitamin D Vital for the Heart 2Health News:Vitamin D Vital for the Heart 3Health News:FAAN Names New CEO 2
... more than 57,000 children found that greater the ...ng poor or having a single mother who is a high sc...g sick, immaterial of race or health insurance cov...ved for long that growing up in physically or ment...
... industry a panel comprising European experts reco...a be approved for sales// in the European Union. T...f. The action of the pill Acomplia (rimonabant) i...t obesity. People on the pill eat less because the...
...ce for Wales published, figures for rates of serio...g MRSA. This step is taken to assure// the public ...h officials to protect the public. John Wardell, ...tion after a hip replacement operation at Abergele...
...to be a common problem with the Middle-aged and ol.... But now, Dr. Najah S. Musacchio, a fellow at Chi...p further in finding out if this problem could hav...er and understand, Musacchio and fellow researcher...
Other Medicine News:Health News:A New Study Shows Social Well Being Plays An Important Part In Childs Health 2Health News:A New Study Shows Social Well Being Plays An Important Part In Childs Health 3
Midstream Catch Kits
Midstream Catch Kits
The BladderScan BVM 6500 enables physicians quickly and noninvasively to determine UEBW (ultrasound estimated bladder weight) and bladder volume using 3-dimensional V-mode ultrasound. The BVM 6500 wa
Silver Wire Coil and helix provide distal shaft column strength and prevents buckling.,Unique Silver Wire Construction eliminates springback and provides for superior concealability.,Anatomically Sha
Medicine Products: